Objectives: Despite evidence for many potential risks, use of benzodiazepines (BZDs) among older adults is common. The authors evaluated the available evidence for BZD effectiveness and tolerability for use in older adults in three psychiatric conditions for which BZDs are commonly prescribed: insomnia, anxiety disorders, and behavioral and psychological symptoms of dementia. Design: Electronic databases, including PubMed/MEDLINE, were searched to identify articles that (1) included patients ≥50 years of age, (2) focused on patients diagnosed with insomnia, anxiety disorders, or behavioral and psychological symptoms of dementia, and (3) were either a randomized, placebo-controlled trial or a randomized trial comparing a BZD with either another psychotropic medication or psychotherapy. Results: Thirty-one studies met the inclusion criteria. Of the three clinical indications evaluated, treatment of insomnia had the greatest available evidence for use of BZDs among older adults, with 21 of 25 trials demonstrating improved sleep outcomes with use of BZDs. Only one trial was found to meet eligibility criteria for BZD use in anxiety disorders, demonstrating benefit over placebo. Five studies for use in behavioral disturbances in dementia were included, of which only one demonstrated improvement over placebo. Conclusion: This systematic review suggests that BZD prescribing to older adults is significantly in excess of what the available evidence suggests is appropriate. Future trials should focus on efforts to reduce both acute and chronic BZD use among older adults while improving access to effective non-pharmacologic treatment alternatives.
D
espite evidence for many potential risks, use of benzodiazepines (BZDs) among older adults is common. Recent national estimates suggest that 8.7% of Americans over age 65 were prescribed BZDs within the past year. 1 Because a proportion of all new users convert to long-term use, 2, 3 long-term use accumulates among patient cohorts as they age, so the prevalence of BZD prescribing is greatest among older adults. 4 Roughly one-third of all BZD use is long term (≥120 days in a recent analysis), with older adults accounting for the greatest proportion of patients with longterm use. 1 Understanding the prescribing of BZDs among older adults is of particular importance in light of the greater risk for polypharmacy and the increased sensitivity to medication side effects within this population. Use of BZDs among older adults has been associated with many adverse effects, including falls, 5 fractures, 6, 7 and motor vehicle accidents. 8, 9 While several studies have suggested a potential association between BZD use and increased risk of dementia, [10] [11] [12] a large, prospective study found no increase in risk with greater BZD exposure. 13 A review of randomized, placebo-controlled trials by Tannenbaum and colleagues, 14 however, demonstrated that BZDs cause amnestic and non-amnestic cognitive impairment. Following opioids, BZDs are the second most common medication class associated with prescription drug overdose mortality, and BZDrelated overdoses have been increasing. 4, 15 While opioids are the most common prescription medication associated with overdose mortality, BZDs are the medication class most commonly combined with opioids in such deaths. 15, 16 In light of these concerns, the U.S. Food and Drug Administration recently issued a black box warning advising potential respiratory suppression and death caused by co-prescribing opioids with other central nervous system depressants, including BZDs. 17 Given these concerns, multiple professional societies have identified the reduction of prescribing BZDs among older adults as a national priority. Since its inception, the American Geriatrics Society Beers Criteria for potentially inappropriate medication use in the elderly have included BZDs, with the most recent update in 2015 now listing all BZDs as potentially inappropriate for older adults. 18 As part of the Choosing Wisely Campaign, the American Geriatrics Society identified use of BZDs in older adults as one of ten things physicians and patients should question. 19 Additionally, the American Psychiatric Association has recommended special caution when prescribing BZDs to older adults, given the high potential for side effects. 20 In light of the high prevalence of BZD use among older adults and the known harms associated with such use, we sought to evaluate the available evidence for their effectiveness and tolerability specifically in older adults. For the purpose of this study, we chose to focus on the three psychiatric conditions for which BZDs are commonly prescribed: insomnia, anxiety disorders, and behavioral and psychological symptoms of dementia.
METHODS

Inclusion and Exclusion Criteria
Articles were included if they (1) included patients ≥50 years of age, (2) focused on patients diagnosed with insomnia, anxiety disorders, or behavioral and psychological symptoms of dementia, and (3) were either randomized, placebo-controlled trials or randomized trials comparing a BZD with either another psychotropic medication (e.g., antidepressant) or psychotherapy. We did not include studies in languages other than English for which an English-language translation was not available. Additionally, studies were excluded if the primary outcomes were not symptoms of insomnia, anxiety disorders, or behavioral and psychological symptoms of dementia (e.g., sleep disturbances, agitation, psychosis).
Search Strategy
Electronic databases including PubMed/MEDLINE were searched from inception through August 2017 to identify studies that met the inclusion criteria. Databases were searched for peer-reviewed, English-language articles using the following combinations of keywords and medical subject headings (MeSH terms) in title, abstract, or index terms: 
Study Selection
One author (LG) screened initial titles and abstracts. Selected abstracts were then screened by two independent authors (LG and DM). Studies were selected for inclusion if two authors agreed that they met eligibility criteria. The extracted data from each study were collected into a data-collection spreadsheet. Abstracted data included total sample size, age range, placebo controlled versus comparison of other treatment, summary of findings, and whether study favored use of a BZD or comparison treatment.
RESULTS
The initial search yielded 2073 results, which was reduced to 661 after excluding studies that were not randomized, clinical trials. Forty-five studies were identified as potentially relevant; the full text was then reviewed by two of the study authors (LG and DM). After review of all potentially relevant studies, the authors initially agreed whether or not to include 39 of the 45 articles (87%). For the other 6, the reviewers were able to reach discussion-based consensus; further review by a third party was unnecessary. Ultimately, 31 studies met inclusion criteria and were included in this review (Supplemental Figure 1 , available at http://links.lww.com/HRP/A72). Findings from those studies are reviewed below, organized by diagnosis type and whether placebo controlled or BZD versus another treatment (e.g., psychotropic medication or psychotherapy).
Insomnia
Twenty-five trials were identified as evaluating BZDs for treating insomnia in older adults. Study sample sizes ranged from 6 to 335 participants (Table 1) . BZDS VERSUS PLACEBO We were able to identify 22 trials comparing use of BZDs with placebo for treating insomnia. Among these trials, 20 studies demonstrated greater improvement in sleep measures with use of BZDs versus placebo. Improvements were generally seen in decreased sleep latency, increased duration of sleep, and reduced nighttime awakenings, provided mostly by patient self-report. However, 3 of the positive trials favoring use of BZDs concluded that specifically compared use of cognitive-behavioral therapy (CBT) for insomnia to use of BZDs in older adults. In that study the authors compared use of temazepam, CBT, combined treatment with temazepam and CBT, or placebo and found that improvements in sleep continuity and efficiency favored combination treatment, then CBT, followed by pharmacotherapy. Sleep improvements were better sustained, however, with the CBT-alone condition than with CBT + BZD or BZD alone.
BZDS VERSUS OTHER TREATMENT Three trials compared BZDs to another treatment for insomnia. Only one of the three studies favored use of a BZD over another medication for treating insomnia. Lachnit and colleagues 43 found that use of oral midazolam was similar in efficacy to, but led to less side effects than, the combination medication Vesparax (combination of hydroxyzine, brallobarbital, and secobarbital), which includes strong anticholinergic and barbiturate components.
Anxiety Disorders
Only one trial was found to meet eligibility criteria, with a sample size of 220 patients (Table 2) . BZDS VERSUS PLACEBO We identified only one study comparing a BZD to placebo for treating anxiety disorders among older adults. This 1982 study by Koepke and colleagues 47 found that, compared to placebo, use of oxazepam was associated with reductions in the Hamilton Anxiety Rating Scale; patients on oxazepam had roughly a 7-point reduction in total score, versus a 3-point reduction in the placebo group.
BZDS VERSUS OTHER TREATMENT No eligible studies were found.
Dementia
A total of five studies met eligibility criteria, with sample sizes ranging from 7 to 610 (Table 3) .
BZDS VERSUS PLACEBO Two trials compared BZD use with placebo for treating patients with dementia; one demonstrated a benefit over placebo. Meehan and colleagues 49 evaluated use of lorazepam and olanzapine intramuscular injections in managing behavioral disturbances in dementia. They found a significant reduction on the Agitation-Calmness Scale, Cohen-Mansfield Agitation Inventory, and Positive and Negative Symptom Scale with use of intramuscular lorazepam. Olanzapine had a longer-lasting effect, however, outperforming the BZD. 
DISCUSSION
This systematic review highlights several key features regarding use of BZDs among older adults. First, the high rate of BZD prescribing among older adults is strikingly out of proportion to the body of evidence supporting such use. Our search identified a total of only 31 trials evaluating use of BZDs across combined indications of insomnia, anxiety disorders, and behavioral disturbances in dementia, with only 2 studies published after 2000. Given the high risk of potential harms associated with use of these medications in older adults, it is concerning that such limited evidence is available to support their efficacy and safety in treating conditions for which they are commonly prescribed. Of the three clinical indications that we evaluated, treatment of insomnia had the greatest available evidence for use of BZDs among older adults, accounting for three-fourths of the total studies evaluated. For insomnia, 21 of 25 trials demonstrated improvement in sleep outcomes with use of BZDs over placebo or another treatment. Among these studies, however, 3 of the positive trials concluded that the high side-effect burden limited the recommended use of BZDs in older adults 33, 40, 42 with an additional study finding no improvement in use of BZDs over CBT for insomnia. 41 Moreover, while the positive trials reported here demonstrated improvement with use of BZDs over placebo or another treatment, the overall magnitude of the treatment effect was relatively small. Many published trials included here followed patients over a short follow-up period, with limited evaluation of longer-term sleep outcomes. Of the 21 trials demonstrating improvement in sleep measures, only 6 of the studies followed patients for more than 14 days.
Additionally, for insomnia, many of the trials included here used patient self-report for sleep measures. Studies suggest that patients may overestimate the potential subjective improvement in sleep with use of pharmacotherapy, with one study finding that use of sedative hypnotics increase total sleep time objectively only by 25 minutes. 53, 54 While some evidence may support use of BZDs for treating insomnia in the short term, little evidence supports chronic use of BZDs for insomnia. 55 Several recent studies have shown that longterm BZD use for insomnia, compared to non-use, is associated with worsening sleep quality, including difficulty falling asleep and more nighttime awakenings. [56] [57] [58] [59] Clinicians may consider use of non-benzodiazepine receptor agonist ("Z-drugs") as a safer alternative, though studies demonstrate a similar concerning side-effect profile for use in older adults, including increased risk of falls, 60 fracture, 61 impaired cognition, 53 and motor vehicle accidents 62 due to morningafter impairment. In addition, various newer studies have established that CBT is an effective treatment for insomnia; though not more effective than BZDs or sedative hypnotics in a general adult population, 46, 63 CBT has none of the associated potential risks.
Despite BZDs being routinely prescribed to older adults for treating anxiety disorders, we were able to find only one randomized, controlled trial to support their use, which was completed 35 years ago. 47 Additionally, for treating anxiety disorders, concern is growing that BZDs may actually reduce the benefit of other more effective therapies. Analyses of treatment of panic disorder demonstrate that concurrent use of BZDs can reduce the effectiveness of exposure-based psychotherapies. 64, 65 For treating posttraumatic stress disorder (PTSD), a recent systematic review and meta-analysis recommends against use of BZD treatment, finding that concurrent use of BZDs and psychotherapy can lead to worse patient outcomes. 66 Despite the lack of efficacy for BZDs in treating symptoms of PTSD, 30% of veterans with PTSD received a BZD prescription in 2012. 67 Finally, limited evidence supports use of BZDs in managing behavioral and psychological symptoms of dementia, with only one study demonstrating a potential benefit with use of intramuscular lorazepam. 49 Across all included trials, BZDs performed worse than antipsychotics in reducing agitation. Since BZDs are not subject to the black box warnings for increased mortality that apply to antipsychotics, 68 some prescribers may consider use of BZDs to be safer than antipsychotics for treating the behavioral and psychological symptoms of dementia. The use of BZDs, however, can still lead to significant harms among these older adults, including paradoxical disinhibition, increased confusion, and worsening agitation, 69 and the evidence for their benefit is less than that for antipsychotics.
The results of this systematic review suggest that BZD prescribing to older adults is significantly in excess of what the available evidence suggests is appropriate. While some limited evidence is available to guide risk-benefit decisions regarding use of BZDs for the above indications, a significant amount of BZD prescribing also appears to occur in the absence of any clear mental health diagnosis or for chronic pain, for which BZDs are not indicated. 2, 3, 70, 71 Where the evidence does not support the prescribing of BZDs, a provider then has only the ample evidence of potential harms associated with use in older adults. Recent analyses of general use of BZDs in older adults suggest that nearly half of patients receiving a BZD have neither a diagnosis of a mental health disorder nor significant psychiatric symptoms to support their use. 3, 70, 72 This study has several limitations. Our inclusion of only randomized, controlled trials limits our sample size of included studies. The results may have been different with inclusion of observational studies. Additionally, we did not assess for potential publication bias or perform a systematic search to account for unpublished data. It is our assumption, however, that trials without significant findings would be more 73 explored both physician and older-adult perspectives on chronic BZD use and on reducing use. Among patients, BZDs were viewed as being very important in managing their anxiety, sleep, and stress. Patients felt that these medications provided them a "lifeline" and feared that, without them, they would not fare well. Patients generally underestimated or were unaware of the potential side effects of their BZD use and resisted the idea of a taper. In Cook and colleagues' companion article focusing on physician attitudes, 74 physicians did not view BZD use among older adults as a health problem and perceived that BZDs were more effective than other available treatment alternatives. Providers assumed that patients would be resistant to changing their BZD dose and perceived that a taper would cause distress for patients. This reluctance from both patients and physicians to discuss tapering may help account for the persistently high use of BZDs among older adults.
While patients may be reluctant to participate in studies of benzodiazepine tapers, evidence supports several successful strategies. Structured algorithms to reduce polypharmacy use among older adults-including use of BZDs-demonstrate successful discontinuation of medications without adverse effects for the patient. 75 In the EMPOWER trial, Tannenbaum and colleagues 76 used direct-to-patient education that successfully encouraged older adults to initiate discussions with their providers regarding safe and appropriate prescribing-which ultimately lead to reduced BZD use. Studies evaluating older adults on chronic BZDs for treating insomnia have shown success from utilizing a combination of CBT with supervised tapering, with the majority of participants that successfully tapered remaining BZD-free at one-year follow-up. 77, 78 Finally, structured interventions providing a written steppeddose reduction tapering schedule for patients have been effective in reducing chronic BZD use among primary care patients. 79 A recent meta-analysis evaluating interventions for reducing BZD use among older adults found that the combination of psychotherapy and supervised BZD tapering resulted in the highest rate of BZD discontinuation-with patients, compared to those on control interventions, having five times greater odds of discontinuing treatment. 80 Use of prescription BZDs among older adults remains a significant concern and ongoing challenge. BZDs are associated with multiple adverse outcomes, and BZDs are the medication class, after opioids, most associated with mortality in overdose. 4 Despite these known harms and relative lack of evidence to support use in conditions such as anxiety disorders and behavioral and psychological symptoms of dementia, BZDs remain widely prescribed to many older adults. While BZD use may be appropriate in select populations, use should be considered only after assessing the potential benefits, risks, and effective alternatives, and following efforts to use evidence-based treatments that pose less risk of harm. While both patients and providers may consider with dread the possibility of stopping a BZD, recent intervention trials have shown promise in reducing BZD use. Future trials should focus on efforts to reduce both acute and chronic BZD use among older adults while improving access to effective non-pharmacologic treatment alternatives.
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